Compartmentalized immune response reflects clinical severity of beryllium disease.
Although beryllium disease has been associated with a bronchoalveolar lavage (BAL) lymphocytosis and T cell-mediated immune response, we do not know if either the BAL cellular profile or the compartmentalized pulmonary response to the antigen reflect the severity of the disease. We studied 110 subjects divided into three groups of subjects: beryllium disease patients (n = 55), beryllium-sensitized patients without disease (n = 8), and control subjects (n = 47). Evaluation included completion of a respiratory symptom questionnaire, clinical examination, chest radiograph, spirometry, body plethysmographic lung volumes, and diffusing capacity (DLCO). In the patient groups, we performed maximal exercise testing with an indwelling arterial line. In addition, we examined BAL and performed blood and BAL beryllium lymphocyte transformation tests (BeLT) as measures of the beryllium-specific T cell-mediated response in these two compartments. In beryllium disease patients we correlated the BAL cellular constituents with clinical parameters indicative of disease severity. Beryllium disease patients exhibited elevated numbers of white cells and lymphocytes in BAL compared with both other groups; however, this lymphocytic alveolitis was significantly obscured in smokers. The BAL cellular constituents correlated with BAL BeLT but not with the blood BeLT. BAL cellular constituents also correlated with the radiographic profusion of small opacities, FEV1/FVC, DLCO, maximal achievable work load, VO2max, and measures of gas exchange at rest and at maximum exercise. We conclude that the lymphocyte-predominant pulmonary inflammatory response in beryllium disease is related to the magnitude of the localized response to antigen and that BAL cellularity, differential cell count, and BeLT reflect beryllium disease clinical severity.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado.
L S
LS
Newman
C
C
Bobka
B
B
Schumacher
E
E
Daniloff
B
B
Zhen
M M
MM
Mroz
T E
TE
King
D001607:Berylliosis / Q000175:diagnosis / Q000276:immunology* / Q000503:physiopathology; D001608:Beryllium / Q000009:adverse effects / Q000494:pharmacology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D002452:Cell Count; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology; D007958:Leukocyte Count; D008168:Lung / Q000000981:diagnostic imaging; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D011859:Radiography; D015656:Respiratory Mechanics; D013601:T-Lymphocytes
D001608:Beryllium